Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom

Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom

То assess angiotensin II receptor blocker effects on platelet aggregation in arterial hypertension (AH) and metabolic syndrome (MS), 34 patients were administered valsartanfor 16 weeks. The dynamics of anthropometry parameters, blood lipids, plasma and platelet lipid peroxidation, blood and blood ce...

Full description

Bibliographic Details
Main Authors:	I. N. Medvedev, T. A. Kumova
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2007-06-01
Series:	Российский кардиологический журнал
Subjects:	arterial hypertension metabolic syndrome platelets valsartan
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/2154

Similar Items

Comparison of platelet hemostasis effects for angiotensin receptor blockers in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2007-08-01)

Rapid normalization of platelet hemostasis in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2008-04-01)

Eprosartan effects on intravascular platelet activity in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2008-02-01)

Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2008-10-01)

Intravascular platelet activity correction by fosinopril in arterial hypertension patients with metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2006-10-01)

ANTIHYPERTENSIVE EFFICACY AND INFLUENCE ON SEXUAL FUNCTION OF VALSARTAN AND VALSARTAN AND HYDROCHLOROTHIAZIDE COMBINATION IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

THE COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF GENERIC AND ORIGINAL VALSARTAN AS A MONOTHERAPY OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE AND BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREE AND METABOLIC SYNDROME
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

ANTIHYPERTENSIVE EFFICACY OF VALSARTAN IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION: THE FIRST RESULTS OF RUSSIAN MULTICENTER OPEN STUDY
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

Increased intravascular platelet activity in metabolic syndrome patients, and its correction by simvastatin treatment
by: N. I. Gromnatsky, et al.
Published: (2004-12-01)

VALSARTAN IN EVERYDAY CLINICAL PRACTICE IN RUSSIA: ANTIHYPERTENSIVE EFFICACY AND INFLUENCE ON SEXUAL FUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

FIXED COMBINATION OF VALSARTAN AND AMLODIPINE: EFFECTS ON THE LEFT VENTRICULAR HYPERTROPHY REGRESSION, ALBUMINURIA REDUCTION AND ENDOTHELIUM FUNCTION IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME
by: Ye. I. Tarlovskaya, et al.
Published: (2016-01-01)

Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction
by: S. V Nedogoda, et al.
Published: (2013-06-01)

NonDpharmaceutical correction of intravascular platelet activity in hypertensive patients
by: I. N. Medvedev
Published: (2005-10-01)

The first results of an international clinical trial VICTORY:the efficacy and safety of antihypertensive valsartan monotherapy and the fixed combination of valsartan and hydrochlorothiazide usingdifferent dosage regimens in patients with 1-2 degree arterial hypertension
by: E Evgen'evna Chazova, et al.
Published: (2015-06-01)

PLATELET HEMOSTASIS DYNAMICS IN SIMVASTATINTREATED PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
by: I. N. Medvedev, et al.
Published: (2010-02-01)

The effectiveness of therapy with valsartan and hydrochlorothiazide and its effect on the left atrial myocardium condition in women with arterial hypertension in postmenopause
by: M. Yu. Kolesnyk, et al.
Published: (2019-12-01)

COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)
by: O. V. Dralova, et al.
Published: (2016-01-01)

Verospiron effects on platelet aggregation in patients with arterial hypertension and abdominal obesity
by: I. N. Medvedev, et al.
Published: (2007-12-01)

Lisinopril effects on platelet activity in patients with arterial hypertension and impaired glucose tolerance
by: I. N. Medvedev, et al.
Published: (2008-06-01)

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
by: Anwar Ali, et al.
Published: (2021-10-01)

CORRECTION OF AGGREGATIVE FUNCTION OF THE TROMBOCYTES IN ARTERIAL HYPERTENSION PATIENTS WITH METABOLIC SYNDROM UNDER THE INFLUENCE OF SIMVASTATINE
by: N. J. Gromnazky, et al.
Published: (2003-12-01)

Effects of verapamil combinations with enalapril or indapamide on plasma, vascular and platelet hemostasis and biochemical markers of endothelial dysfunction in patients with arterial hypertension and metabolic syndrome
by: N. M. Krasnova, et al.
Published: (2008-06-01)

EFFICACY OF FIXED COMBINATION OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN COMPLEX THERAPY OF THE PATIENT OF VERY HIGH CARDIOVASCULAR RISK
by: I. M. Sokolov, et al.
Published: (2015-12-01)

BISOPROLOL AND METFORMIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
by: V. A. Nevzorova, et al.
Published: (2015-12-01)

Pathogenesis of arterial hypertension within the metabolic syndrome
by: A S Ryazanov, et al.
Published: (2003-03-01)

CHANGES IN THE PARAMETERS OF 24-HOUR BLOOD PRESSURE MONITORING AND ARTERIAL STIFFNESS IN PATIENTS WITH HYPERTENSION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATED WITH VALSARTAN
by: N. A. Karoli, et al.
Published: (2015-09-01)

P6.4 PLATELET ACTIVITY IN TEENAGE BOYS WITH PRIMARY ARTERIAL HYPERTENSION
by: Indre Bauziene*, et al.
Published: (2015-11-01)

P6.3 PLATELET ACTIVITY IN TEEN GIRLS WITH PRIMARY ARTERIAL HYPERTENSION
by: Indre Bauziene*, et al.
Published: (2015-11-01)

Relationship between metabolic syndrome components in patients with resistant arterial hypertension
by: I. P. Shmakova, et al.
Published: (2021-06-01)

AFFECTIVE DISORDERS IN WOMEN WITH ARTERIAL HYPERTENSION IN COMBINATION WITH METABOLIC SYNDROME
by: Roman A. Yaskevich, et al.
Published: (2022-06-01)

AFFECTIVE DISORDERS IN MEN WITH ARTERIAL HYPERTENSION IN COMBINATION WITH METABOLIC SYNDROME
by: Roman A. Yaskevich, et al.
Published: (2022-08-01)

Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
by: Bin Wang, et al.
Published: (2022-03-01)

Valsartan Decreases Platelet Activity and Arterial Thrombotic Events in Elderly Patients with Hypertension
by: Fang Wu, et al.
Published: (2015-01-01)

Hypocaloric diet in thrombosis risk reduction among patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev
Published: (2006-02-01)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
by: Cong Zhao, et al.
Published: (2022-11-01)

Improving the cognitive functions in the middle-aged patients with essential arterial hypertension after the treatment with amlodipine/valsartan single-pill combination
by: O. D. Ostroumova, et al.
Published: (2019-03-01)

Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
by: S. S. Yakushin, et al.
Published: (2004-12-01)

EFFECTIVENESS OF VASCULAR WALL ACTIVITY CORRECTION IN PATIENTS WITH ARTERIAL HYPERTENSION, METABOLIC SYNDROME, AND OCULO-VASCULAR OCCLUSION
by: I. N. Medvedev, et al.
Published: (2010-06-01)

Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study
by: Lee KJ, et al.
Published: (2023-04-01)

Possible combinations of antihypertensive drugs at treatment of arterial hypertension at patientswith metabolic syndrome
by: Viktoriya Borisovna Mychka, et al.
Published: (2009-03-01)